The GSK plc vaccine Arexvy receives expanded approval from the U.S. Food and Drug Administration, allowing use in adults aged 18–49 who face a higher risk of severe respiratory illness caused by Respiratory Syncytial Virus (RSV).
GSK plc has announced a significant expansion in the approved use of its respiratory syncytial virus (RSV) vaccine, marking an important step forward in the prevention of serious respiratory illness among adults in the United States. The decision by the U.S. Food and Drug Administration (FDA) broadens the approved age indication of the company’s vaccine AREXVY (Respiratory Sy18 to 49 years who are at increased risk of low caused by RSV.
This regulatory milestone reflects growing recognition of the burden that RSV places not only on older adults but also on younger adults with underlying health conditions. With the new approval, healthcare providers will now have an additional preventive option for a wider segment of the adult population who are vulnerable to severe respiratory complications from RSV infection.
Respiratory syncytial virus is a common respiratory virus that infects the lungs and breathing passages. While many infections result in mild, cold-like symptoms, RSV can lead to severe disease in certain high-risk populations, particularly older adults, infants, and individuals with chronic health conditions.
Previously, AREXVY had been approved in the United States for the prevention of RSV-related lower respiratory tract disease in adults aged 60 years and older,adults aged. The lates18 to 49 who face higher medical risk to receive the vaccine as a preventive measure.
However, it is important to note that the vaccine is not approved for use in pregnant individuals,
According to Sanjay Gurunathan, Head of Vaccines and Infectious Diseases Research and Development at GSK plc,
He emphasized that many younger adults living with chronic medical conditions face elevated risk of severe illness when infected with RSV. Expanding vaccine access to this group could help reduce serious health outcomes and alleviate strain on healthcare systems during respiratory virus seasons.
The Burden
Although RSV is commonly associated with infants and older adults, the virus also has a measurable impact on younger adults, particularly those with pre-existing medical conditions. In the United States, the annual burden of RSV among adults aged 18 to 49 is substantial.
Public health data estimate that RSV infection among this age group results in approximately:
- 17,000 hospitalizations each year
- 277,000 emergency department visits
- 1.97 million outpatient medical visits
Most severe cases requiring hospitalization occur in individuals with underlying health conditions that make them more vulnerable to respiratory complications.
- Chronic cardiopulmonary diseases such as asthma or heart disease
- Kidney o
- Obesity
- Dia
- Other chronic medical conditions that compromise immune or respiratory function
For individuals living with these conditions, RSV infection can escalate quickly into serious lower respiratory tract disease, which may require hospitalization or intensive medical care. Expanding vaccination to this younger, high-risk group may therefore help reduce both severe illness and the broader healthcare burden.
Clinical Evidence Supporting the Approval
The FDA’s decision to broaden the approved age indication was supported by evidence from a Phase IIIb clinical trial, identified as NCT06389487. This study evaluated the immune response generated by the vaccine in adults aged 18 to 49 who are at increased risk of RSV-related disease.
The results demonstrated that the immune response in this younger high-risk population was non to the immune response previously observed in adults aged 60 years and older. In clinical research, non-inferiority means that the vaccine produced a comparable immune response, suggesting that it is likely to provide similar protection against RSV infection.
Earlier evidence supporting the vaccine’s effectiveness came from the Phase, which demonstrated vaccine efficacy in preventing RSV-related lower respiratory tract disease.
Together, these studies provided the clinical data necessary for regulators to conclude that the vaccine could safely and effectively be extended to a younger adult population at risk.
Safety Profile and Common Side Effects
The safety profile of AREXVY observed in the Phase IIIb study was consistent with the safety findings previously established in the broader clinical development program.
Participants in the trial generally tolerated the vaccine well, and the most commonly reported adverse events were mild to moderate in severity. These reactions typically occurred within four days of vaccination and included:
- Injection site pain
- Fatigue
- Muscle pain (myalgia)
- Headache
- Joint pain (arthralgia)
These types of side effects are commonly associated with vaccines and usually resolve within a short period without requiring medical intervention.
The consistency of the safety findings across multiple studies helped reinforce the confidence of regulators in approving the expanded indication.
Implications for Public Health
Expanding vaccine eligibility to younger adults at risk could have meaningful implications for public health. Respiratory viruses such as RSV can place significant strain on hospitals and healthcare resources, particularly during seasonal outbreaks when multiple respiratory pathogens circulate simultaneously.
By protecting vulnerable individuals before infection occurs, vaccination can help reduce:
- Hospital admissions
- Emergency department visits
- Severe respiratory complications
Reducing these outcomes may help alleviate pressure on healthcare systems, particularly during peak respiratory virus seasons.
Furthermore, preventing severe RSV infections in high-risk adults may also reduce long-term complications associated with respiratory illness and improve overall quality of life for individuals with chronic health conditions.
GSK’s Broader RSV Strategy
The expanded approval also reflects GSK plc’s broader strategy to develop and distribute vaccines targeting RSV across multiple populations and regions. The company has invested heavily in research and development focused on respiratory viruses and infectious diseases, aiming to address major unmet medical needs.
In addition to the United States, GSK continues to pursue regulatory submissions in multiple countries and regions to broaden global access to its RSV vaccine. These efforts are part of the company’s long-term goal to expand prevention strategies for RSV across diverse populations.
As health authorities worldwide increasingly recognize the impact of RSV on adults, demand for preventive solutions such as vaccines is expected to grow. Expanding vaccine availability may play a critical role in improving disease prevention and reducing healthcare costs associated with respiratory infections.